3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neoplasm Metastasis
2
Lung Neoplasms
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thyroid Cancer, Papillary
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Pleural Effusion, Malignant
1
Osteoporosis
1
Neoplasms
1
Lymphatic Metastasis
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Interventions
Magnetic Resonance Spectroscopy
8
Iodine-131
8
Thyrotropin Alfa
5
trametinib
4
selpercatinib
4
dabrafenib
4
Vemurafenib
4
lenvatinib
3
cabozantinib
3
Sunitinib
3
Specimen Handling
3
Sorafenib
3
Radiofrequency Ablation
3
Fluorodeoxyglucose F18
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
vandetanib
2
entrectinib
2
cobimetinib
2
X-Rays
2
Trastuzumab
2
Thyroid (USP)
2
Rosiglitazone
2
Radiotherapy
2
Nivolumab
2
Interviews as Topic
2
Gefitinib
2
Everolimus
2
Bortezomib
2
AZD 6244
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Cancer, Papillary
×
Spectrum Analysis
×
Clear all
NCT03470259
2024-04-16
TARGET
University Medical Center Groningen
Phase 1
Completed
19 enrolled